Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Blackman

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Optics Express|May 5, 2019
Gallium Phosphide photoanode coated with TiO<sub>2</sub> and CoO<sub>x</sub> for stable photoelectrochemical water oxidationM Alqahtani, S Ben-Jabar, M Ebaid, et al.
Communications Biology|July 29, 2025
Terrestrial land cover shapes fish diversity in a major subtropical river catchmentHeng Zhang, Rosetta C Blackman, Reinhard Furrer, et al.
Journal of Pharmaceutical Sciences|April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumorsDaniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 8, 2013
Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidationDavid A Bershas, Daniele Ouellet, Donna B Mamaril-Fishman, et al.
Journal of Clinical Pharmacology|December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenibA Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Lancet (London, England)|May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Pharmacology and Therapeutics|January 15, 2016
An accessible pharmacodynamic transcriptional biomarker for notch target engagementK Q Tanis, A A Podtelezhnikov, S C Blackman, et al.
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Optics Express|May 5, 2019
Gallium Phosphide photoanode coated with TiO<sub>2</sub> and CoO<sub>x</sub> for stable photoelectrochemical water oxidationM Alqahtani, S Ben-Jabar, M Ebaid, et al.
Communications Biology|July 29, 2025
Terrestrial land cover shapes fish diversity in a major subtropical river catchmentHeng Zhang, Rosetta C Blackman, Reinhard Furrer, et al.
Journal of Pharmaceutical Sciences|April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumorsDaniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 8, 2013
Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidationDavid A Bershas, Daniele Ouellet, Donna B Mamaril-Fishman, et al.
Journal of Clinical Pharmacology|December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenibA Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Lancet (London, England)|May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Pharmacology and Therapeutics|January 15, 2016
An accessible pharmacodynamic transcriptional biomarker for notch target engagementK Q Tanis, A A Podtelezhnikov, S C Blackman, et al.
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 5